What will I learn?

Delivered over six comprehensive modules, this course covers:

• Four Principles of Disease Assessment

• RECIST Disease Assessments

• iRECIST Disease Assessments

• Prostate Cancer Working Group 3 Disease Assessments

• Haematology Disease Assessments (Lugano)

• International Myeloma Working Group (IMWG) Uniform Response Criteria

Key Learning Objectives:

Understand the Importance of Disease Assessments:

• Grasp the crucial role that accurate disease assessments play in evaluating cancer treatments, ensuring efficacy and precision from the outset.

Develop Essential Skills and Knowledge:

• Gain the necessary expertise to strategically plan and execute tumour assessments, leading to reliable and meaningful clinical trial outcomes.

Explore the Four Core Principles of Tumour Assessments:

1. Differentiate tumour assessments in clinical trials from other medical settings.

2. Familiarize yourself with international response criteria for various disease types.

3. Identify and mitigate potential biases in data collection and reporting.

4. Establish robust data collection programs to accurately assess disease status and treatment responses.

Expected Outcomes:

By the end of this course, you will have the confidence and competence to strategically plan and carry out tumor assessments, ensuring that your clinical trials yield precise and meaningful results.

Who will I learn from? 

Duncan Colyer, Senior Manager, Clinical Research, VCCC Alliance

Felicity McLeay, Research Nurse, Haematology, Parkville Cancer Clinical Trials Unit

Javad Saghebi, Nuclear Medicine Physician, Peter MacCallum Cancer Center

Kortnye Smith, Medical Oncologist, Peter MacCallum Cancer Center 

and other contributions from experts in the field.